Loading clinical trials...

Changes in Gene Transcription and Immunophenotypes Following Mepolizumab Treatment for Asthma | Clinical Trials | Clareo Health

COMPLETED

Changes in Gene Transcription and Immunophenotypes Following Mepolizumab Treatment for Asthma

Exploratory Investigation of Changes in Gene Transcription and Immunophenotypes Following Mepolizumab Treatment for Asthma

NCT05002621•Mayo Clinic

View on ClinicalTrials.gov

Summary

The purpose of this study is to identify differentially expressed gene transcripts after initiation of mepolizumab in individuals with severe eosinophilic asthma (SEA).

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Age ≥ 18 years old.
•Diagnosis of SEA by a health care provider
•History of an absolute eosinophil count ≥ 300/mm\^3
•Prescription for mepolizumab provided during course of routine clinical care but mepolizumab not yet started

Exclusion Criteria

•Age \< 18 years old.
•Pregnancy.
•Currently using or have used within 3 months of the initial baseline visit any biologic or immunomodulatory therapy with the exception of #3.
•Currently using or any prior use of rituximab.
•History of upper/lower respiratory tract infection or asthma exacerbation within the previous four weeks of the first baseline visit.
•Any prior history of malignancy, autoimmune disease, or immune deficiency.
•Any other significant medical issue as determined by the principal investigator.

Locations (1)

Mayo Clinic in Rochester

Rochester, Minnesota, United States

Key Dates

Start Date

February 16, 2021

Primary Completion Date

February 13, 2023

Completion Date

December 11, 2025

Last Updated

March 18, 2026

Enrollment

ACTUAL participants

Conditions

Eosinophilic Asthma

Interventions

Observational

OTHER

Beyond EOsinophils: proteoMICS to Identify Potential Biomarker of Organ Damage and Response to MEPOLIZUMAB in EGPA

NCT07343661

EGPA - Eosinophilic Granulomatosis With PolyangiitisSevere Asthma+1 more

View study

ACTIVE_NOT_RECRUITINGPHASE3

STEP: Phase IIIb Study of Benralizumab to Step-down Maintenance Therapy in Patients With Severe Eosinophilic Asthma

NCT06465485

Severe Eosinophilic Asthma

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 18, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Changes in Gene Transcription and Immunophenotypes Following Mepolizumab Treatment for Asthma

Inclusion Criteria

Exclusion Criteria

Beyond EOsinophils: proteoMICS to Identify Potential Biomarker of Organ Damage and Response to MEPOLIZUMAB in EGPA

STEP: Phase IIIb Study of Benralizumab to Step-down Maintenance Therapy in Patients With Severe Eosinophilic Asthma

A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Eosinophilic Asthma

A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma.

A Real World Study to Capture Clinical and Patient Centered Outcomes in Adults With Severe Eosinophilic Asthma Treated With Benralizumab.

Identification of Autoantigens in EGPA and Severe Eosinophilic Asthma